These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28074293)

  • 1. [Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?].
    Buerke M; Hoffmeister HM
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):105-110. PubMed ID: 28074293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks].
    Dülgeroglu J; Schmidt D
    Praxis (Bern 1994); 2018 Apr; 107(9-10):485-493. PubMed ID: 29690851
    [No Abstract]   [Full Text] [Related]  

  • 3. [Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].
    Gulba DC; Broscaru L
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):83-91. PubMed ID: 28144727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monitoring of NOAC].
    Zotz RB; Weißbach L
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):92-98. PubMed ID: 28083625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Simeon L; Wuillemin WA
    Ther Umsch; 2016; 73(10):561-566. PubMed ID: 28045358
    [No Abstract]   [Full Text] [Related]  

  • 7. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
    Robert-Ebadi H; Righini M
    Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
    [No Abstract]   [Full Text] [Related]  

  • 8. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
    Proietti M; Lip GY
    Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin-K antagonists: A retrospective German claims data analysis.
    Engelbertz C; Marschall U; Feld J; Makowski L; Lange SA; Freisinger E; Gerß J; Breithardt G; Faldum A; Reinecke H; Köppe J
    J Intern Med; 2024 Oct; 296(4):362-376. PubMed ID: 39221828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease].
    Mohebbi N
    Praxis (Bern 1994); 2018 Jun; 107(13):683-687. PubMed ID: 29921184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
    Ruff CT; Giugliano RP; Antman EM
    Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
    Morimoto T; Crawford B; Wada K; Ueda S
    J Cardiol; 2015 Dec; 66(6):466-74. PubMed ID: 26162944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
    De Caterina R; Ageno W; Agnelli G; Chan NC; Diener HC; Hylek E; Raskob GE; Siegal DM; Verheugt FWA; Lip GYH; Weitz JI
    Thromb Haemost; 2019 Jan; 119(1):14-38. PubMed ID: 30597497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
    Darius H
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
    Sjögren V; Byström B; Renlund H; Svensson PJ; Oldgren J; Norrving B; Själander A
    PLoS One; 2017; 12(7):e0181000. PubMed ID: 28700711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on Direct Oral AntiCoagulants (DOACs).
    Koscielny J; Rosenthal C; von Heymann C
    Hamostaseologie; 2017; 37(4):267-275. PubMed ID: 29582929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review: An overview and analysis of novel oral anticoagulants and their dental implications.
    Fortier K; Shroff D; Reebye UN
    Gerodontology; 2018 Jun; 35(2):78-86. PubMed ID: 29493031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
    Finks SW; Trujillo TC; Dobesh PP
    Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.